Synchronized Immunization NotifiCations
NCT02710318 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 15348
Last updated 2019-09-06
Summary
Immunization is one of the most effective public health interventions. Yet, nationally coverage has consistently fallen short of national goals, and has remained for the most part stagnant. The continued presence of vaccine-preventable diseases poses a threat to public health. In addition to needed improvement of immunization coverage for the general pediatric/adolescent population, some children with chronic medical conditions need specific additional immunizations, yet many fail to receive them.
Immunization reminders for providers in the electronic health record (EHR) are a type of clinical decision support (CDS) that can reduce missed immunization opportunities. One limitation of these reminders is that they generally depend only on data local to the EHR, which can be incomplete due to record scatter, leading to inaccurate alerts. An Immunization Information System (IIS), also known as an immunization registry, is a population-based system that collects immunization data primarily for children and adolescents from providers at a regional or state level.
The investigators seek to couple bidirectional exchange of IIS immunization information and forecasting tools with patient level medical history from the EHR to deliver accurate, patient-specific EHR immunization reminders.
Conditions
- Vaccination
Interventions
- BEHAVIORAL
-
Electronic immunization alert
Immunization alert in the electronic health record
Sponsors & Collaborators
-
New York Presbyterian Hospital
collaborator OTHER -
Seattle Children's Hospital
collaborator OTHER -
Agency for Healthcare Research and Quality (AHRQ)
collaborator FED - lead OTHER
Principal Investigators
-
Melissa Stockwell, MD MPH · Columbia University
Study Design
- Allocation
- RANDOMIZED
- Purpose
- HEALTH_SERVICES_RESEARCH
- Masking
- SINGLE
- Model
- CROSSOVER
Eligibility
- Max Age
- 17 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2017-06-06
- Primary Completion
- 2018-06-05
- Completion
- 2018-06-05
Countries
- United States
Study Locations
More Related Trials
-
Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine in Healthy Infants
NCT03512288 ·Status: COMPLETED ·Phase: PHASE2
-
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine
NCT00345358 ·Status: COMPLETED ·Phase: PHASE3
-
Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age
NCT07348692 ·Status: RECRUITING ·Phase: PHASE3
-
Multicentre Booster & Immune Memory Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine or a Single Dose of 23-valent Plain Polysaccharide Vaccine in Healthy Children Aged 11-18 Mths, Previously Vaccinated in Study 103488
NCT00307567 ·Status: COMPLETED ·Phase: PHASE2
-
Systems Biology of PNEUMOVAX®23 and PREVNAR 13®
NCT01307449 ·Status: COMPLETED ·Phase: NA
-
Study Evaluating Antibody Response Of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) 24 Months After Toddler Dose.
NCT01026038 ·Status: COMPLETED ·Phase: PHASE3
-
A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Infants
NCT06720038 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Study of 7-valent Pneumococcal Conjugate Vaccine in Children With Idiopathic Nephrotic Syndrome
NCT01346007 ·Status: UNKNOWN ·Phase: PHASE4
-
Safety and Immunogenicity of 7-Valent Pneumococcal Conjugate Vaccine in Children Receiving Solid Organ Transplants
NCT00213265 ·Status: COMPLETED ·Phase: PHASE3
-
Assessment of Novel Pneumococcal Conjugate Vaccination Scheduled in UK Infants
NCT02918708 ·Status: WITHDRAWN ·Phase: PHASE4
-
Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Healthy Children Aged 15 Months to 17 Years
NCT00761631 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age
NCT06824181 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Safety and Immunogenicity Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine
NCT00370227 ·Status: COMPLETED ·Phase: PHASE3
-
Maternal Immunization To Prevent Infant Otitis Media
NCT00617682 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Comparison of Immune Response Using 2 Vaccination Schedules Using Inactivated Polio Vaccine
NCT00137696 ·Status: COMPLETED ·Phase: NA
-
Safety, Tolerability, and Immunogenicity Study of a 31-Valent Pneumococcal Conjugate Vaccine (VAX-31) in Adults
NCT06151288 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Immune Response In Children Revaccinated With Pneumococcal Conjugate Vaccine
NCT00853749 ·Status: COMPLETED ·Phase: PHASE3
-
Using Pneumococcal Vaccines in Combination for Maximum Protection From Ear and Lung Infections in First 3 Years of Life
NCT01735084 ·Status: COMPLETED ·Phase: PHASE4
-
PCV10 Immunogenicity Study Nepal 2015
NCT02385513 ·Status: COMPLETED ·Phase: PHASE4
-
Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49
NCT07284654 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Study Comparing 13-valent Pneumococcal Conjugate Vaccine With 7-valent Pneumococcal Conjugate Vaccine
NCT00373958 ·Status: COMPLETED ·Phase: PHASE3
-
Immunological Memory Against Pneumococcus Induced by 3 Infant PCV 13 Vaccination Schedules
NCT03405805 ·Status: UNKNOWN
-
A Phase 1, Randomized, Controlled, Observer-blinded Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Healthy Adults Aged 18 to 49 Years
NCT02955160 ·Status: COMPLETED ·Phase: PHASE1
-
Reminder Emails to Improve Pneumococcal Vaccine Completion at 12 Months of Age
NCT06000397 ·Status: RECRUITING ·Phase: NA
-
Consistency, Immunogenicity, and Safety of Three Batches of 15-valent Pneumococcal Conjugate Vaccine
NCT05939219 ·Status: UNKNOWN ·Phase: NA